Seronegative palindromic rheumatism: what are we talking about? Comment on the article by Yang et al

Summary: According to the study results, patients with PL arthritis can be classified into four groups based on the presence of MEFV mutations and ACPA/RF antibodies, each with different clinical evolution and therapeutic responses.

Summary: Palindromic rheumatism (PR) is an intermittent arthritis that may progress to rheumatoid arthritis (RA). Research suggests that autoimmunity plays a key role in PR, with most patients exhibiting a characteristic autoantibody profile similar to that seen in RA. Studies have analyzed the rate of progression to RA and the effectiveness of drug therapies for treating PR.